Gibson Christopher 4

What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), reported three related transactions on March 9, 2026: two conversions of derivative securities (each for 20,000 shares) and a gift of 20,000 shares. The conversions and the gift were reported at $0 per share (conversion/gift, not an open‑market trade). One conversion is listed as an acquisition of 20,000 shares and the other conversion and the gift are recorded as dispositions.

Key Details

• Transaction date: 2026-03-09; Form 4 filed 2026-03-11 (appears timely).
• Transactions recorded at $0.00 per share (conversion/gift), not a market purchase/sale.
• Reported items: Conversion of derivative security — 20,000 shares (acquired); Gift — 20,000 shares (disposed); Conversion of derivative security — 20,000 shares (disposed; derivative).
• Shares owned after the transactions: not specified in the filing.
• Relevant footnote: F1 — Class B common stock is convertible into Class A common stock at the holder’s option and has no expiration date.
• No cash proceeds were reported (gift and conversion).

Context
Conversions of Class B shares into Class A (recorded at $0) reflect a change in share class/ownership form rather than a purchase. Gifts are transfers that do not indicate a buy/sell market view and produce no cash to the insider. This filing reports conversion/gift activity by a director and is informational for shareholders tracking insider movements.